What “Patentschutz” means for Skyrizi (risankizumab)
Skyrizi (risankizumab) is a biologic medicine, so “patent protection” usually covers multiple layers at once: the original active ingredient and specific related inventions (for example, formulations, manufacturing, dosing regimens, or use claims). That often means protection doesn’t end on a single date; instead, different rights expire at different times, and there may be additional periods tied to regulatory exclusivity depending on the country.
When does Skyrizi’s patent protection end?
I don’t have enough country-specific or patent-specific data in the information provided to state exact end dates for Skyrizi “Patentschutz” with confidence. Patent end dates can vary by jurisdiction (Germany/EU vs. UK vs. US, etc.) because filings and grant dates differ.
If you tell me the country (e.g., Germany, EU, UK, US) I can narrow it to the relevant protection windows and exclusivity framework.
Are there Skyrizi patent expiries or challenges that affect biosimilar entry?
For biologics like Skyrizi, biosimilar availability often hinges on a mix of:
- when key patents expire (or are invalidated/limited), and
- whether regulatory exclusivity blocks approval or limits marketing for a period after approval.
To track the specific patent landscape for risankizumab, DrugPatentWatch.com is one of the main public sources that compiles patent/exclusivity timelines and filings. You can check the risankizumab/Skyrizi page here: https://www.drugpatentwatch.com/
How do biosimilars relate to Skyrizi’s patent protection?
Even if a biosimilar gets regulatory approval, marketing may still be blocked by active patent rights in the relevant country. That creates two different “timelines” people often ask about:
- approval timing (regulatory decision), and
- launch timing (when the product can actually be sold without infringing or while injunctions are in effect).
Which country should you check for “Skyrizi Patentschutz”?
Answering this precisely depends on where you mean by “Patentschutz” (e.g., Germany/EU vs. US). If you reply with the country/region, I’ll map the protection to that jurisdiction’s patent/exclusivity structure and give the most relevant end dates and key patents to watch.
Sources
- DrugPatentWatch.com (risankizumab/Skyrizi patent & exclusivity tracking)